[1189] Re-Evaluation of Immunohistochemical Markers in Endometrial Adenocarcinomas

Haiyan Liu, Hong Yin, Hanlin Wang, Fan Lin. Geisinger Medical Center, Danville, PA; UCLA Medical Center, Los Angeles, CA

Background: When working on a tumor of unknown origin, a metastatic adenocarcinoma from the endometrium may present a diagnostic challenge because of the inconsistent data from the literature and complicated immunostaining profiles for endometrial adenocarcinoma (EAD). In this study, we re-evaluate the expression of an extensive panel of biomarkers in endometrial adenocarcinomas using a single immunostaining system (Ventana XT).
Design: We immunohistochemically evaluated the expression of 1) epithelial markers (AE1/3, CAM5.2, CK7, CK20, CK17, CK19, CK903, EMA); 2) mucin gene products (MUC1, MUC2, MUC4, MUC5AC, MUC6); 3) tumor suppressor genes and transcription factors (ER, PR, p53, beta-catenin, ERG, GATA3, WT-1, CDX2, pVHL); and 4) tumor-associated proteins (TTF-1, napsin A, p16, HepPar1, glypican 3, SALL4, OCT4, PAX8, RCC, GCDFP15, mammaglobin, S100P, IMP3, maspin, MOC31, CEA, CA19-9, CD10, CD15, villin, and P504S) on 128 cases of endometrial adenocarcinoma endometrioid type (FIGO I 32 cases, FIGO II 58 cases, and FIGO III 38 cases) on tissue microarray sections. The staining intensity distribution was recorded.
Results: The positive staining results from selected antibodies are summarized in Table 1. Twelve of 128 cases (9.4%) showed diffuse (4+) and strong p16 positivity. All cases were negative for CK20, SALL4, OCT4, MUC2, HepPar1, villin, GCDFP15, and S100P.

Table 1. Summary of immunostaining results on selected antibodies
AntibodyEAD FIGO 1 (N=32)EAD FIGO 2 (N=58)EAD FIGO 3 (N=38)Positive Cases (%)
CK729/3252/5834/3889.8%
CK172/320/580/381.6%
MUC132/3258/5838/38100%
Vimentin31/3252/5835/3892%
ER32/3258/5835/3897.7%
PR30/3257/5838/3897.7%
Mammoglobin19/3245/5818/3864%
TTF-10/322/580/381.6%
Napsin A3/320/580/382.3%
Glypican 30/320/584/383%
pVHL0/322/580/381.6%
Maspin12/3215/584/3824%
CEA4/329/585/3814%
p1632/3257/5838/3899%
P504S7/3234/5824/3850.8%
CDX20/321/580/380.8%
PAX832/3258/5837/3899%
RCC0/324/582/384.7%
ERG0/321/580/380.8%



Conclusions: These data demonstrate that 1) mammaglobin and other tumor/organ-specific markers can be positive in a significant percentage of cases; 2) nearly all cases are positive for ER, PR and PAX8 regardless of tumor grade; 3) 10% of cases can be negative for CK7 and vimentin; and 4) caution should be taken when using p16 to differentiate endometrial primary from endocervical primary since close to 10% of cases are diffusely and strongly positive for p16.
Category: Gynecologic & Obstetrics

Wednesday, March 21, 2012 1:00 PM

Poster Session VI # 201, Wednesday Afternoon

 

Close Window